Hypoglycemia

Pregnant women with type 1 diabetes and impaired hypoglycemia awareness have greater fear and more episodes of severe hypoglycemia than those with normal awareness, particularly in the first trimester, according to study data.

A novel once-weekly formulation of basal insulin was safe and effective in adults with long-standing type 2 diabetes, with lower rates of documented and nocturnal hypoglycemia over 32 weeks compared with insulin degludec, phase 2 data show.

Although much attention has focused on weight gain in type 2 diabetes, more research is needed on weight management interventions for people with type 1 diabetes, according to a speaker.

Eli Lilly is voluntarily recalling one lot of glucagon emergency kits at the patient level after a product complaint reporting a vial of glucagon was in liquid instead of powder form, according to an FDA press release.

People with diabetes who require emergency assistance due to hypoglycemia were less likely to require parenteral therapy if they had a higher glucose level, normal consciousness or received oral glucose treatment, according to study data.

Parent-reported hypoglycemia fear and diabetes-specific family conflict may predict HbA1c trajectories for children aged 5 to 9 years with recent-onset type 1 diabetes, according to findings published in Diabetic Medicine.

A next-generation glucagon analog provided rapid and effective treatment of severe hypoglycemia for children and adults with type 1 diabetes, without the need to reconstitute lyophilized powder used in traditional glucagon rescue kits.

Severe hypoglycemic and hyperglycemic events correlated with increased risk for dementia among older adults with type 1 diabetes, according to a longitudinal cohort study of more than 2,800 patients published in Neurology.

Hypoglycemia is common, easily missed and often underappreciated, and endocrinologists must adopt approaches to prevent and treat the condition in their patients with diabetes, according to a speaker.

The FDA granted breakthrough therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes, according to a press release from vTv Therapeutics.